FDA Crackdown on Compounded Semaglutide: What Patients Need to Know

The FDA officially resolved the semaglutide shortage that had been in place since 2022. During the shortage, compounding pharmacies were legally permitted under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act to produce compounded versions of semaglutide. With the shortage resolved, that legal pathway has narrowed significantly. The FDA has begun issuing cease-and-desist letters to compounding pharmacies still producing semaglutide, arguing they no longer have the shortage exemption to compound copies of commercially available drugs. Novo Nordisk, the manufacturer of Ozempic and Wegovy, has aggressively pursued legal action against compounding pharmacies, filing lawsuits alleging trademark infringement and patient safety concerns.

The impact on patients has been significant: Cost increases: Compounded semaglutide typically cost $150-350/month. Brand-name Wegovy costs $1,300+/month without insurance. Many patients face a 3-5x price increase. Supply disruptions: Some telehealth providers that relied exclusively on compounded semaglutide have been forced to pivot or shut down entirely. Patients have reported abrupt treatment interruptions. Treatment gaps: The transition period has left some patients without medication for weeks, potentially causing weight regain and metabolic disruption. Insurance barriers: While coverage is expanding, many insurers still don't cover GLP-1 medications for weight loss, leaving patients in a difficult position.

The situation remains legally complex. Several compounding pharmacies have challenged the FDA's position in court, arguing that: 1. Patient access should be prioritized over manufacturer profits 2. The shortage may not truly be resolved given ongoing supply chain issues 3. Compounding pharmacies serve a legitimate medical need for customized dosing Federal courts have issued mixed rulings. Some have granted temporary injunctions allowing certain 503B outsourcing facilities to continue production. Others have sided with the FDA and Novo Nordisk. Congress has also gotten involved, with bipartisan legislation proposed to protect patient access to compounded GLP-1 medications during the transition period.

If you've been affected by the compounding crackdown, here are your current options: Brand-name medications: Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved for weight loss. While expensive at retail, manufacturer savings programs and insurance coverage can reduce costs significantly. Eli Lilly's direct vials: Zepbound single-dose vials are available through LillyDirect at $399-549/month — significantly less than retail pricing for pen injectors. Insurance appeals: If your insurer denies coverage, you have the right to appeal. Many providers offer assistance with prior authorizations and appeals. Patient assistance programs: Both Novo Nordisk and Eli Lilly offer savings cards and patient assistance programs for eligible patients. Switching medications: If semaglutide is no longer accessible, tirzepatide (Zepbound/Mounjaro) may be available through different channels at competitive pricing.

As this situation evolves, be aware of these red flags: Providers still offering "compounded semaglutide" at very low prices may be operating outside FDA guidelines. This doesn't necessarily mean the medication is unsafe, but it does carry additional regulatory risk. Some bad actors have emerged selling counterfeit or substandard products labeled as compounded semaglutide. Only obtain medications through licensed, verified pharmacies. Be cautious of providers who guarantee uninterrupted compounded semaglutide supply — the legal landscape is shifting rapidly and no provider can guarantee future availability.